Drugs / rAAV2tYF-PR1.7-hCNGB3
rAAV2tYF-PR1.7-hCNGB3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02599922 | Apr 2016 → Jul 2022 overdue | achromatopsia | Beacon Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV2tYF-PR1.7-hCNGB3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02599922 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant adeno-associated virus vector” NCT02599922 ↗ |
| Route | Other | “administered to one eye by subretinal injection” NCT02599922 ↗ |
| Target | CNGB3 | “expresses the CNGB3 gene” NCT02599922 ↗ |